Literature DB >> 28283766

Autoantibodies to types I and IV collagen and heart valve disease in systemic lupus erythematosus/antiphospholipid syndrome.

José Pardos-Gea1, Josefina Cortés-Hernández2, Jesus Castro-Marrero2, Eva Balada2, José Ordi-Ros2.   

Abstract

Introduction/objectives autoantibodies to types I and IV collagen have been described in rheumatic fever and infective endocarditis. We tried to elucidate if an autoimmune response against collagens I and IV exists, associated with heart valve disease in systemic lupus erythematosus (SLE) and antiphospholipid syndrome (APS). A cohort of 172 patients with SLE (n = 79), primary APS (PAPS, n = 83), and secondary APS (n = 10) were assessed for valvulopathy by transthoracic echocardiograms. Autoantibodies to types I and IV collagen were assessed in patients and 50 controls, setting autoantibody positivity at two standard deviations above the mean antibody level of controls. Positive anticollagen IV antibody rate was significantly higher in SLE patients (17.7%) in respect to the rest of groups (PAPS 2.4%, controls 2%; P = 0.001). Percentage of positive autoantibodies to collagen I was similar in SLE and APS cohort of patients with and without valvular disease (48.4 vs 51.6%, respectively; P = 0.45). Percentage of positive autoantibodies to collagen IV was increased but not significantly in SLE and APS cohort of patients with respect to those without valvular disease (62.5 vs 37.5%, respectively; P = 0.08). Mean (standard deviation) levels of positive anticollagen I and IV antibodies did not differ between patients with and without valvular disease (85.6 ± 55 vs 81 ± 85 U/ml, respectively; P = 0.86 for anticollagen I) (0.05 ± 0.02 vs 0.12 ± 0.16 U/ml, respectively; P = 0.34 for anticollagen IV). Our data indicate a lack of association of autoantibodies to types I and IV collagen with heart valve disease in SLE and APS.

Entities:  

Keywords:  Antiphospholipid; Collagen autoantibodies; Lupus; Type I collagen; Type IV collagen; Valve heart disease

Mesh:

Substances:

Year:  2017        PMID: 28283766     DOI: 10.1007/s10067-017-3594-9

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  23 in total

1.  Task Force on Catastrophic Antiphospholipid Syndrome (APS) and Non-criteria APS Manifestations (I): catastrophic APS, APS nephropathy and heart valve lesions.

Authors:  R Cervera; M G Tektonidou; G Espinosa; A R Cabral; E B González; D Erkan; S Vadya; H E Adrogué; M Solomon; G Zandman-Goddard; Y Shoenfeld
Journal:  Lupus       Date:  2011-02       Impact factor: 2.911

2.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus.

Authors:  M C Hochberg
Journal:  Arthritis Rheum       Date:  1997-09

3.  Measurement of autoimmune response against collagen types I, III, and IV by enzyme-linked immunosorbent assay, and its application in infective endocarditis.

Authors:  M L De Buyzere; I K De Scheerder; J R Delanghe; J H Robbrecht; D L Clement; R J Wieme
Journal:  Clin Chem       Date:  1989-02       Impact factor: 8.327

4.  Overlapping humoral autoimmunity links rheumatic fever and the antiphospholipid syndrome.

Authors:  M Blank; I Krause; L Magrini; G Spina; J Kalil; S Jacobsen; H J Thiesen; M W Cunningham; L Guilherme; Y Shoenfeld
Journal:  Rheumatology (Oxford)       Date:  2006-05-16       Impact factor: 7.580

5.  Libman-Sacks endocarditis in the antiphospholipid syndrome: immunopathologic findings in deformed heart valves.

Authors:  L Ziporen; I Goldberg; M Arad; M Hojnik; J Ordi-Ros; A Afek; M Blank; Y Sandbank; M Vilardell-Tarres; I de Torres; A Weinberger; R A Asherson; Y Kopolovic; Y Shoenfeld
Journal:  Lupus       Date:  1996-06       Impact factor: 2.911

6.  Collagen autoantibodies in patients with vasculitis and systemic lupus erythematosus.

Authors:  L W Moreland; R E Gay; S Gay
Journal:  Clin Immunol Immunopathol       Date:  1991-09

7.  Echocardiography at diagnosis of antiphospholipid syndrome provides prognostic information on valvular disease evolution and identifies two subtypes of patients.

Authors:  J Pardos-Gea; J Ordi-Ros; G Avegliano; J Cortés-Hernández; E Balada; A Evangelista; M Vilardell
Journal:  Lupus       Date:  2010-01-12       Impact factor: 2.911

8.  [Anti-type II collagen antibodies in collagen disease].

Authors:  Y Fukasawa; S Kano
Journal:  Rinsho Byori       Date:  1993-08

9.  Antibodies to α5 chain of collagen IV are pathogenic in Goodpasture's disease.

Authors:  Zhao Cui; Ming-Hui Zhao; Xiao-Yu Jia; Miao Wang; Shui-Yi Hu; Su-Xia Wang; Feng Yu; Kyle L Brown; Billy G Hudson; Vadim Pedchenko
Journal:  J Autoimmun       Date:  2016-04-23       Impact factor: 7.094

Review 10.  Cardiac interstitium in health and disease: the fibrillar collagen network.

Authors:  K T Weber
Journal:  J Am Coll Cardiol       Date:  1989-06       Impact factor: 24.094

View more
  2 in total

1.  An Autoantigen Atlas From Human Lung HFL1 Cells Offers Clues to Neurological and Diverse Autoimmune Manifestations of COVID-19.

Authors:  Julia Y Wang; Wei Zhang; Victor B Roehrl; Michael W Roehrl; Michael H Roehrl
Journal:  Front Immunol       Date:  2022-03-24       Impact factor: 8.786

2.  A Master Autoantigen-ome Links Alternative Splicing, Female Predilection, and COVID-19 to Autoimmune Diseases.

Authors:  Julia Y Wang; Michael W Roehrl; Victor B Roehrl; Michael H Roehrl
Journal:  bioRxiv       Date:  2021-08-04
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.